Developer docs
API playgroundTry for free, no card

Search company profiles

Iterion Therapeutics

Full company profile

uuid0002fim

Namestring
Iterion Therapeutics
Legal namestring
Iterion Therapeutics
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Iterion Therapeutics is a clinical-stage biopharmaceutical company headquartered in Houston, Texas, developing small-molecule therapeutics for cancers driven by dysregulated Wnt/beta-catenin signaling. The company's lead and sole clinical asset, tegavivint (formerly BC2059), is a first-in-class small-molecule inhibitor of TBL1 (Transducin beta-like protein 1) that disrupts the TBL1-beta-catenin transcriptional complex and selectively degrades nuclear beta-catenin, a mechanism intended to address a previously 'undruggable' node in the Wnt pathway without the toxicities of upstream inhibitors. Iterion also has early R&D into second-generation TBL1 inhibitors, suggesting a platform ambition beyond the lead asset.

The company's primary clinical focus is advanced hepatocellular carcinoma (HCC), where approximately 40% of patients harbor Wnt/beta-catenin mutations and no targeted therapies exist. Phase 1/2 data presented at ASCO 2026 showed a 22% overall response rate, 89% disease control rate, and 8-month median progression-free survival in second- and third-line WPAM+ patients, with a favorable safety profile. Beyond HCC, Iterion is expanding tegavivint into metastatic colorectal cancer (Phase 1/2 trial initiated March 2026 in Houston), relapsed/refractory pediatric osteosarcoma (trial initiated February 2026 at Emory/Aflac Cancer Center with FDA Orphan Drug and Pediatric Rare Disease Designations), and earlier-stage signals in desmoid tumors, large B-cell lymphomas, AML, and NSCLC via investigator-sponsored collaborations with Ohio State, the Children's Oncology Group, and Cancer Research UK.

Iterion is a privately held, pre-revenue company that funds development through a mix of non-dilutive grants and equity. Major capital includes $26 million in CPRIT Product Development Awards and a $17 million financing round led by Lumira Ventures with Sante Ventures and Viva BioInnovator participation; the board also includes representatives from OrbiMed and Lumira. The company employs 11–50 people and is led by CEO Rahul Aras (PhD), CMO Ovid Trifan (MD, PhD), CSO Steve Horrigan (PhD), and COO Jean Chang, with founder Sunil Sharma. The go-to-market upon potential FDA approval is expected to rely on enterprise field sales to oncologists and hospital systems, with the addressable market spanning more than 500,000 Wnt-driven cancers annually across multiple indications.

Short descriptiontext

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing tegavivint, a first-in-class TBL1 inhibitor targeting Wnt/beta-catenin-driven cancers. Its lead indication is advanced hepatocellular carcinoma, with expansion trials underway in colorectal cancer and pediatric osteosarcoma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer therapeutics, Wnt pathway inhibitors, clinical-stage biopharmaceutical, targeted oncology drugs, small molecule therapeutics
Industry2 codes
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Targeted Oncology Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Upon successful clinical development and FDA approval, Iterion intends to commercialize tegavivint for Wnt-driven cancers including hepatocellular carcinoma, colorectal cancer, and osteosarcoma.

iteriontherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing tegavivint, a first-in-class small-molecule TBL1 inhibitor that selectively degrades nuclear beta-catenin to shut down oncogenic Wnt/β-catenin signaling. The lead product is being advanced in clinical trials across multiple Wnt-driven cancer indications including advanced hepatocellular carcinoma, metastatic colorectal cancer, and pediatric osteosarcoma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 22% overall response rate in Phase 1/2 trial for advanced HCC
+3 more records
Product overview1 text field

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing a single lead product, tegavivint, as a first-in-class small molecule inhibitor targeting the Wnt/β-catenin pathway. Tegavivint is being advanced across multiple cancer indications including advanced hepatocellular carcinoma (HCC), metastatic colorectal cancer, osteosarcoma, desmoid tumors, large B-cell lymphomas, acute myeloid leukemia, and non-small cell lung cancer. The company's differentiated approach targets TBL1 to promote nuclear β-catenin degradation, positioning tegavivint as the most advanced Wnt/β-catenin inhibitor in clinical development.

Product and service1 record
1Tegavivint
CategoryTargeted oncology therapeutics
Description

Tegavivint is a first-in-class small-molecule TBL1 inhibitor that selectively degrades nuclear beta-catenin to shut down oncogenic Wnt/β-catenin signaling. It is the most advanced Wnt/β-catenin inhibitor in clinical development, with applicability across more than 500,000 cancers annually, and is being evaluated in advanced hepatocellular carcinoma (primary focus), metastatic colorectal cancer, and pediatric osteosarcoma.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-10
Description

Emory University-sponsored clinical trial evaluating tegavivint in combination with gemcitabine for patients with relapsed or refractory osteosarcoma. The trial is conducted at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Collaboration with Ohio State University Comprehensive Cancer Center for Phase 1 clinical trial of tegavivint in patients with c-Myc-overexpressing relapsed or refractory large B-cell lymphomas.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

NCI-supported clinical trials group sponsoring the first clinical study for tegavivint in the pediatric population, representing an investigator-sponsored Phase 1/2 clinical trial in pediatric cancers.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Cancer Research UK on preclinical study of tegavivint in beta-catenin mutant hepatocellular carcinoma, with results presented at the 34th EORTC-NCI-AACR Symposium.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company targeting the RAS/MAPK pathway. Comparable as a similarly-sized clinical-stage biotech with a single mechanistic focus and multi-indication development strategy, though in a different signaling pathway.

2Theseus Pharmaceuticals
TypeDirect peer
Description

Clinical-stage targeted oncology company developing kinase inhibitors across multiple indications. Comparable as a venture-backed clinical-stage oncology company with pipeline breadth across tumor types.

TypeDirect peer
Description

Clinical-stage precision oncology company developing targeted therapies for RAS-driven cancers. Comparable as a clinical-stage biotech with a first-in-class mechanism targeting a historically difficult oncology pathway.

TypeDirect peer
Description

Clinical-stage oncology biotech developing chromatin-based therapeutics. Comparable as a clinical-stage company targeting transcriptional regulation machinery in cancer with a first-in-class mechanism.

TypeDirect peer
Description

Clinical-stage precision oncology company developing allosteric mutation-targeted therapies. Comparable as a venture-backed clinical-stage biotech with a mechanism-focused discovery approach.

6Nuvalent
TypeDirect peer
Description

Clinical-stage precision oncology company developing targeted kinase inhibitors. Comparable as a clinical-stage biotech focused on a single mechanism deployed across multiple oncology indications.

TypeDirect peer
Description

Clinical-stage pediatric and adult oncology company with FDA breakthrough and orphan designations. Comparable as a clinical-stage oncology company pursuing pediatric rare cancer indications with regulatory designations.

TypeDirect peer
Description

Clinical-stage targeted oncology company developing kinase inhibitors. Comparable as a venture-backed clinical-stage precision oncology biotech with multi-indication development strategy.

TypeEmerging player
Description

Clinical-stage biotech developing Wnt pathway-targeting therapeutics for regenerative medicine and ophthalmology. Comparable through direct targeting of the same Wnt signaling pathway, though in different therapeutic areas.

TypeBroad incumbent
Description

Large oncology incumbent developing multiple targeted therapies including HCC therapies (atezolizumab+bevacizumab standard of care). Comparable as the dominant incumbent in the HCC and broader oncology landscape Iterion operates in.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Iterion Therapeutics

Targeted Oncology Therapeuticsiteriontherapeutics.com

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing tegavivint, a first-in-class TBL1 inhibitor targeting Wnt/beta-catenin-driven cancers. Its lead indication is advanced hepatocellular carcinoma, with expansion trials underway in colorectal cancer and pediatric osteosarcoma.

What Iterion Therapeutics does

Iterion Therapeutics is a clinical-stage biopharmaceutical company headquartered in Houston, Texas, developing small-molecule therapeutics for cancers driven by dysregulated Wnt/beta-catenin signaling. The company's lead and sole clinical asset, tegavivint (formerly BC2059), is a first-in-class small-molecule inhibitor of TBL1 (Transducin beta-like protein 1) that disrupts the TBL1-beta-catenin transcriptional complex and selectively degrades nuclear beta-catenin, a mechanism intended to address a previously 'undruggable' node in the Wnt pathway without the toxicities of upstream inhibitors. Iterion also has early R&D into second-generation TBL1 inhibitors, suggesting a platform ambition beyond the lead asset.

The company's primary clinical focus is advanced hepatocellular carcinoma (HCC), where approximately 40% of patients harbor Wnt/beta-catenin mutations and no targeted therapies exist. Phase 1/2 data presented at ASCO 2026 showed a 22% overall response rate, 89% disease control rate, and 8-month median progression-free survival in second- and third-line WPAM+ patients, with a favorable safety profile. Beyond HCC, Iterion is expanding tegavivint into metastatic colorectal cancer (Phase 1/2 trial initiated March 2026 in Houston), relapsed/refractory pediatric osteosarcoma (trial initiated February 2026 at Emory/Aflac Cancer Center with FDA Orphan Drug and Pediatric Rare Disease Designations), and earlier-stage signals in desmoid tumors, large B-cell lymphomas, AML, and NSCLC via investigator-sponsored collaborations with Ohio State, the Children's Oncology Group, and Cancer Research UK.

Iterion is a privately held, pre-revenue company that funds development through a mix of non-dilutive grants and equity. Major capital includes $26 million in CPRIT Product Development Awards and a $17 million financing round led by Lumira Ventures with Sante Ventures and Viva BioInnovator participation; the board also includes representatives from OrbiMed and Lumira. The company employs 11–50 people and is led by CEO Rahul Aras (PhD), CMO Ovid Trifan (MD, PhD), CSO Steve Horrigan (PhD), and COO Jean Chang, with founder Sunil Sharma. The go-to-market upon potential FDA approval is expected to rely on enterprise field sales to oncologists and hospital systems, with the addressable market spanning more than 500,000 Wnt-driven cancers annually across multiple indications.

Iterion Therapeutics firmographics

Firmographics
Name
Iterion Therapeutics
Legal name
Iterion Therapeutics
Website
https://iteriontherapeutics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Iterion Therapeutics is a clinical-stage biopharmaceutical company developing tegavivint, a first-in-class TBL1 inhibitor targeting Wnt/beta-catenin-driven cancers. Its lead indication is advanced hepatocellular carcinoma, with expansion trials underway in colorectal cancer and pediatric osteosarcoma.
Ownership category
akta.pro rank

Iterion Therapeutics industry classification

Industry
Product category
Targeted Oncology Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cancer therapeutics
  • Wnt pathway inhibitors
  • Clinical-stage biopharmaceutical
  • Targeted oncology drugs
  • Small molecule therapeutics

Where Iterion Therapeutics is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Iterion Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Sales: Pre-revenue clinical-stage biopharmaceutical company. Upon successful clinical development and FDA approval, Iterion intends to commercialize tegavivint for Wnt-driven cancers including hepatocellular carcinoma, colorectal cancer, and osteosarcoma.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Iterion Therapeutics product offering

Product offering

Core offering

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing tegavivint, a first-in-class small-molecule TBL1 inhibitor that selectively degrades nuclear beta-catenin to shut down oncogenic Wnt/β-catenin signaling. The lead product is being advanced in clinical trials across multiple Wnt-driven cancer indications including advanced hepatocellular carcinoma, metastatic colorectal cancer, and pediatric osteosarcoma.

Product overview

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing a single lead product, tegavivint, as a first-in-class small molecule inhibitor targeting the Wnt/β-catenin pathway. Tegavivint is being advanced across multiple cancer indications including advanced hepatocellular carcinoma (HCC), metastatic colorectal cancer, osteosarcoma, desmoid tumors, large B-cell lymphomas, acute myeloid leukemia, and non-small cell lung cancer. The company's differentiated approach targets TBL1 to promote nuclear β-catenin degradation, positioning tegavivint as the most advanced Wnt/β-catenin inhibitor in clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tegavivint Tegavivint is a first-in-class small-molecule TBL1 inhibitor that selectively degrades nuclear beta-catenin to shut down oncogenic Wnt/β-catenin signaling. It is the most advanced Wnt/β-catenin inhibitor in clinical development, with applicability across more than 500,000 cancers annually, and is being evaluated in advanced hepatocellular carcinoma (primary focus), metastatic colorectal cancer, and pediatric osteosarcoma.

Quantifiable outcome

  • 22% overall response rate in Phase 1/2 trial for advanced HCC
  • +3 more outcomes

Companies that use Iterion Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

Iterion Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Iterion Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Iterion Therapeutics competitors and assessment

Company assessment

Direct peers

  • Erasca: Clinical-stage precision oncology company targeting the RAS/MAPK pathway. Comparable as a similarly-sized clinical-stage biotech with a single mechanistic focus and multi-indication development strategy, though in a different signaling pathway.
  • Theseus Pharmaceuticals: Clinical-stage targeted oncology company developing kinase inhibitors across multiple indications. Comparable as a venture-backed clinical-stage oncology company with pipeline breadth across tumor types.
  • Revolution Medicines: Clinical-stage precision oncology company developing targeted therapies for RAS-driven cancers. Comparable as a clinical-stage biotech with a first-in-class mechanism targeting a historically difficult oncology pathway.
  • Foghorn Therapeutics: Clinical-stage oncology biotech developing chromatin-based therapeutics. Comparable as a clinical-stage company targeting transcriptional regulation machinery in cancer with a first-in-class mechanism.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric mutation-targeted therapies. Comparable as a venture-backed clinical-stage biotech with a mechanism-focused discovery approach.
  • Nuvalent: Clinical-stage precision oncology company developing targeted kinase inhibitors. Comparable as a clinical-stage biotech focused on a single mechanism deployed across multiple oncology indications.
  • Day One Biopharmaceuticals: Clinical-stage pediatric and adult oncology company with FDA breakthrough and orphan designations. Comparable as a clinical-stage oncology company pursuing pediatric rare cancer indications with regulatory designations.
  • Cogent Biosciences: Clinical-stage targeted oncology company developing kinase inhibitors. Comparable as a venture-backed clinical-stage precision oncology biotech with multi-indication development strategy.

Emerging players

  • Surrozen: Clinical-stage biotech developing Wnt pathway-targeting therapeutics for regenerative medicine and ophthalmology. Comparable through direct targeting of the same Wnt signaling pathway, though in different therapeutic areas.

Broad incumbents

  • Genentech (Roche): Large oncology incumbent developing multiple targeted therapies including HCC therapies (atezolizumab+bevacizumab standard of care). Comparable as the dominant incumbent in the HCC and broader oncology landscape Iterion operates in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Iterion Therapeutics compliance and trust

Trust signal

Compliance2 records

Iterion Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Iterion Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Iterion Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Iterion Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iterion Therapeutics

What does Iterion Therapeutics do?

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing tegavivint, a first-in-class small-molecule TBL1 inhibitor that selectively degrades nuclear beta-catenin to shut down oncogenic Wnt/β-catenin signaling. The lead product is being advanced in clinical trials across multiple Wnt-driven cancer indications including advanced hepatocellular carcinoma, metastatic colorectal cancer, and pediatric osteosarcoma.

Is Iterion Therapeutics a public or private company?

Iterion Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Iterion Therapeutics founded?

Iterion Therapeutics was founded in 2015. It employs 11 to 50 people.

Where is Iterion Therapeutics based?

Iterion Therapeutics is headquartered in Houston, United States, in the North America region.

How does Iterion Therapeutics make money?

One revenue line is on record: pharmaceutical Drug Sales.

Who are Iterion Therapeutics's main competitors?

Direct peers on record are Erasca, Theseus Pharmaceuticals, Revolution Medicines, Foghorn Therapeutics, Black Diamond Therapeutics, Nuvalent, Day One Biopharmaceuticals and Cogent Biosciences. Surrozen is listed as an emerging player. Genentech (Roche) is listed as a broad incumbent.

Does Iterion Therapeutics have an API?

No public API is recorded for Iterion Therapeutics.

What industry is Iterion Therapeutics in?

Iterion Therapeutics's product category is Targeted Oncology Therapeutics. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOsteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth | DelveInsightDelveInsight forecasts the osteosarcoma market to grow from about $60 million in 2025 to a higher value by 2036, driven by eight emerging therapies. The market is projected to expand at a 9% CAGR through 2036, with OST-HER2 expected to generate $37 million by 2036.citybizIterion Therapeutics Adds Manuel Aivado and Bob Smith as Tegavivint Pipeline ExpandsIterion Therapeutics appointed Manuel Aivado and Bob Smith as independent directors to support the expansion of its tegavivint oncology pipeline. The appointments provide expertise in clinical development and strategic partnering as the company advances tegavivint into metastatic colorectal cancer and other Wnt-driven indications beyond its initial hepatocellular carcinoma program.PR NewswireIterion Therapeutics Strengthens Board with Additions of Manuel Aivado, MD, PhD and Bob SmithIterion Therapeutics announced the appointment of Manuel Aivado and Bob Smith as new independent board members to strengthen its leadership team. These strategic additions aim to support the clinical development of lead asset tegavivint for hepatocellular carcinoma and metastatic colorectal cancer, leveraging the appointees' expertise in oncology drug advancement and strategic partnering.PR NewswireIterion Therapeutics Reports First Clinical Validation of Tegavivint as a Targeted Therapy for Wnt-Driven Advanced HCC in Oral Presentation at 2026 ASCO Annual MeetingIterion Therapeutics announced positive initial data from its Phase 1/2 trial of tegavivint in advanced hepatocellular carcinoma, showing a 22% overall response rate, 89% disease control rate, and 8 months median progression-free survival in second- and third-line patients with Wnt-pathway activating mutations. The therapy demonstrated tumor shrinkage in approximately 40% of evaluable patients with WPAM+ tumors while no tumor shrinkage was observed in patients without WPAMs, marking the first clinical validation of tegavivint as a targeted therapy for Wnt-driven cancers. Iterion is advancing clinical development in additional Wnt-driven cancers including metastatic colorectal cancer and pediatric osteosarcoma.BioSpaceIterion Therapeutics Reports First Clinical Validation of Tegavivint as a Targeted Therapy for Wnt-Driven Advanced HCC in Oral Presentation at 2026 ASCO Annual MeetingIterion Therapeutics reported positive Phase 1/2 data for tegavivint in Wnt-pathway mutated advanced HCC at the 2026 ASCO meeting. In second- and third-line patients, the drug achieved a 22% overall response rate, 89% disease control, and 8-month median progression-free survival. The company plans further development for mCRC and other Wnt-driven tumors.PR NewswireIterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual MeetingIterion Therapeutics announced that tegavivint, its first-in-class TBL1 inhibitor for Wnt/β-catenin-driven cancers, will be featured in three presentations at the 2026 ASCO Annual Meeting in Chicago, including a rapid oral abstract session presenting Phase 1/2 dose-finding data in advanced hepatocellular carcinoma, which is the third-leading cause of cancer death globally. The ASCO presentations follow recent milestones including dosing of first patients in metastatic colorectal cancer and pediatric osteosarcoma trials, with growing scientific interest in TBL1 as a druggable target. The company has received $26 million in Product Development Awards from the Cancer Prevention and Research Institute of Texas.PR NewswireIterion Presents New Data on First-in-Class TBL1 Inhibitor Tegavivint, Targeting Wnt-Driven Cancers at AACR Annual MeetingIterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor tegavivint will be presented at the 2026 AACR Annual Meeting, highlighting the company's differentiated approach to targeting the Wnt/β-catenin pathway by disrupting the TBL1–β-catenin transcriptional complex to promote nuclear β-catenin degradation. The company recently completed a Phase 1 study in advanced hepatocellular carcinoma demonstrating encouraging clinical responses and durable disease control in heavily pre-treated patients, and has initiated a Phase 1 study in colorectal cancer while preparing to advance into Phase 2 development in HCC. Iterion has received $26 million in Product Development Awards from the Cancer Prevention and Research Institute of Texas (CPRIT) to support its pipeline development.AijournIterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient DosedIterion Therapeutics has dosed the first patient at HonorHealth Research Institute in a Phase 1/2 clinical trial evaluating tegavivint for metastatic colorectal cancer, expanding its clinical development beyond hepatocellular carcinoma. Tegavivint is a first-in-class small molecule inhibitor of the Wnt/β-catenin pathway, which is activated in over 90% of colorectal cancer patients, representing a significant unmet medical need with no FDA-approved targeted therapies available. The company has received $26 million in Product Development Awards from the Cancer Prevention and Research Institute of Texas to support the development.PR NewswireIterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient DosedIterion Therapeutics has dosed the first patient in a Phase 1/2 clinical trial at HonorHealth Research Institute evaluating tegavivint, its first-in-class Wnt/β-catenin pathway inhibitor, for metastatic colorectal cancer. The expansion builds on encouraging monotherapy activity and favorable safety data previously observed in hepatocellular carcinoma, with over 90% of colorectal cancer patients harboring Wnt-pathway activating mutations despite no FDA-approved drugs currently targeting this pathway. Colorectal cancer accounts for over 1.9 million new cases annually and is the second leading cause of cancer-related death in the U.S.PR NewswireIterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory OsteosarcomaIterion Therapeutics announced that the first patient has been dosed in a clinical study evaluating tegavivint, a first-in-class Wnt/β-catenin inhibitor, in combination with gemcitabine for patients with relapsed or refractory osteosarcoma. The trial is sponsored by Emory University and conducted at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, supported by funding from the Peach Bowl LegACy Fund. The drug has received both Orphan Drug Designation and Pediatric Rare Disease Designation from the U.S. FDA, building on prior clinical data showing tolerability and monotherapy activity in hepatocellular carcinoma and desmoid tumors.